> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Keros Therapeutics Authorizes Up To $5 Million In Buybacks Following $20 Million Drug Payment
- URL: https://www.bullished.co/keros-therapeutics-authorizes-up-to-5-million-in-buybacks-following-20-million-drug-f978de1e/
- Published: 2026-11-16T21:21:05.000Z
- Updated: 2026-11-16T21:21:05.000Z
- Description: Management expects cash to fund operations into 2029, accounting for the licensing payment and planned repurchases.
- Author: Matteo Parrino
- Tags: SEC Filings, KROS, Industry: Healthcare

[Keros Therapeutics](https://www.bullished.co/tag/kros/), which develops drugs that are not yet approved for sale, authorized [up to $5 million](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/kros-20261116.htm?ref=bullished.co) in stock buybacks Monday following a $20 million drug-development payment. The company said in its SEC filing that it expects to fund operations into 2029, accounting for both the payment and repurchases.

## A Trial Dose Unlocks Cash

Takeda Pharmaceuticals U.S.A., Keros’ licensing partner for elritercept, made the [milestone payment](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) in November after the first patient was dosed in the drug’s ELRiSE MF trial for myelofibrosis.

Keros had [cash of $259.5 million](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/kros-20261116.htm?ref=bullished.co) on September 30\. Management’s funding projection uses that balance, adds the licensing proceeds and accounts for the buyback. It expects those resources to cover operating expenses and capital spending into 2029 under its current operating plans.

## Permission To Buy, Not A Commitment

Management can buy common shares on the open market or through other legally permitted methods. The authorization sets a spending ceiling; Keros has no obligation to buy a particular number of shares or spend a particular amount.

Keros can [change or stop](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) the program at any time, including suspending it. Share prices, economic and market conditions, contractual restrictions and other considerations will determine the timing and size of purchases.

## Two Drugs Anchor Development

Keros’ research targets faulty signaling by the transforming growth factor-beta family of proteins, which regulates tissue growth and repair. Its protein-based drug candidates address disorders affecting tissues including muscle, bone, fat, heart and blood.

Rinvatercept anchors its neuromuscular business and is being developed for Duchenne muscular dystrophy and amyotrophic lateral sclerosis. Elritercept anchors its blood-disorder business, targeting low blood cell counts—including anemia and low platelet counts—in patients with myelodysplastic syndromes and myelofibrosis.

Under a license agreement effective January 16, 2025, Takeda handles elritercept’s development, manufacturing and commercialization worldwide except mainland China, Hong Kong and Macau.

Keros has a history of losses and depends on the success of those drug candidates. Its development work also depends on outside parties for manufacturing and studies, and clinical trials can face delays in starting, enrolling patients or finishing.

The buyback remains discretionary, while Keros’ estimate of funding into 2029 remains tied to its current operating plans.

Learn

- [Item 8.01: other events →](https://www.bullished.co/learn/8-k-items-explained/#item-801-other-events)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Keros Therapeutics, Inc. (KROS)](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/kros-20261116.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit exhibit991111626pr.htm — Keros Therapeutics, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001664710/000166471026000072/exhibit991111626pr.htm?ref=bullished.co) — SEC EDGAR
- [Keros Therapeutics Announces Additional $5 Million Share](https://www.globenewswire.com/news-release/2026/11/16/3404089/0/en/keros-therapeutics-announces-additional-5-million-share-repurchase-authorization.html?ref=bullished.co) — globenewswire.com

### More on Keros Therapeutics

- [Keros Turns A $14.2 Million Quarterly Profit As Takeda License Revenue Reaches $40 Million](https://www.bullished.co/keros-turns-a-14-2-million-quarterly-profit-as-takeda-license-revenue-reaches-40-million-59e2970c/)
- [Keros Therapeutics Triggers $20 Million Takeda Milestone — Separate $20 Million Payment Received](https://www.bullished.co/keros-therapeutics-triggers-20-million-takeda-milestone-separate-20-million-payment-291a9b44/)
- [Keros Therapeutics Doses First Patient In Mid-Stage Rinvatercept Trial For Duchenne Muscular Dystrophy](https://www.bullished.co/keros-therapeutics-doses-first-patient-in-mid-stage-rinvatercept-trial-for-duchenne-b9bd4824/)

[All Keros Therapeutics (KROS) coverage →](https://www.bullished.co/tag/kros/)